Baxter 2007 Investor Conference March 14, 2007
|
|
- Adrian Holmes
- 5 years ago
- Views:
Transcription
1 Joy A. Amundson is a corporate vice president of Baxter Healthcare Corporation and president of the company s BioScience business. In this position, she is responsible for the development and worldwide marketing of Baxter s biopharmaceutical, vaccine and biosurgery products. Prior to joining Baxter in 2004, Ms. Amundson was a principal of Amundson Partners, Inc., a healthcare consulting firm. She also served in a variety of executive positions at Abbott Laboratories for more than 20 years, including as president of that company s Ross Products division. Ms. Amundson also served in several sales and brand management roles during a six-year tenure at Procter & Gamble. Ms. Amundson is a member of the board of directors of specialty medical device company INAMED Corp.; biopharmaceuticals company ILEX, Inc., and Advocate Lutheran General Hospital in suburban Chicago. She holds a bachelor of arts degree in journalism and advertising from the University of Wisconsin and a master s of management degree from Northwestern University s Kellogg Graduate School of Business. Peter J. Arduini is a corporate vice president of Baxter Healthcare Corporation and president of the company's Medication Delivery business, a leader in the development and manufacturing of a wide range of products focused on delivering critical fluids and drugs to patients. Prior to joining Baxter in March 2005, Mr. Arduini worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses. In addition to having served in sales management, Mr. Arduini also oversaw marketing, market research, product design and engineering program development for its radiology and cardiology franchise. His last role with General Electric Healthcare was as global general manager of its cat scan (CT) and functional imaging business, a $2 billion capital equipment and innovation-intensive business. Prior to joining General Electric Healthcare, Mr. Arduini spent four years with Procter & Gamble. Mr. Arduini received his bachelor s degree in marketing from Susquehanna University and a master s in management from Northwestern University s Kellogg School of Management. Kenneth E. Burhop, Ph.D., is vice president and global scientific lead for Baxter s Medication Delivery business. Dr. Burhop joined Baxter in From 1990 to 2003, he assumed positions of increasing responsibility in Baxter s Hemoglobin Therapeutics Program, ultimately being named project leader and vice president of R&D for the Second Generation Recombinant Hemoglobin Program. Dr. Burhop received his bachelor s degree in zoology from the University of Wisconsin- Milwaukee, a master of science degree in veterinary science/physiology from the University of Wisconsin-Madison and a doctorate in veterinary science/physiology, also from the University of Wisconsin-Madison. Prior to joining Baxter, Dr. Burhop completed an NIH Pulmonary Research Postdoctoral Fellowship at the Albany Medical College in Albany, New York.
2 Robert M. Davis is a corporate vice president and chief financial officer of Baxter International Inc., overseeing Baxter s global financial operations. Mr. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served as director of corporate financial planning. He held numerous positions, including tax counsel and assistant treasurer. As assistant treasurer, he had responsibility for overseeing the global treasury operations, including cash flow planning, capital markets, working capital management and affiliate funding worldwide. Mr. Davis earned his juris doctorate from Northwestern University School of Law and his master s degree from Northwestern University s Kellogg Graduate School of Management, after graduating from Miami University with a bachelor s degree in finance. Hartmut Ehrlich, M.D., is vice president, Global Research and Development for Baxter s BioScience business. Dr. Ehrlich joined Baxter in 1995 as medical director for its former Biotech business. He was named vice president, Global Clinical R&D in 2003 and assumed his current position in Dr. Ehrlich is based in Vienna, Austria. Dr. Ehrlich came to Baxter from Sandoz, now Novartis, and was based in Germany and Switzerland. He spent several years in basic protein research and patient care at the Department of Medicine, Hematology-Oncology of Indiana University and the Lilly Laboratories for Clinical Research in Indianapolis, Indiana. He also worked at the Department of Molecular Biology at the Central Laboratory of the Dutch Red Cross in Amsterdam, The Netherlands, and the Kerckhoff-Clinic of the Max-Planck-Foundation in Bad Nauheim, Germany. Dr. Ehrlich received his medical degree from the University of Giessen, Germany, and completed his doctorate at the Clinical Research Unit for Blood Coagulation and Thrombosis of the Max-Planck-Foundation. Dr. Ehrlich has authored and co-authored over 100 scientific publications and book chapters and is associated with the development and licensing of numerous biopharmaceutical products in the areas of hematology-oncology, immunology, critical care, hemophilia, vaccines and biosurgery. Camille I. Farhat is general manager of Baxter s Global Infusion Systems business unit within the Medication Delivery business. Before joining Baxter in February 2006, Mr. Farhat was vice president of business development at Medtronic and served earlier as vice president and global general manager of the company s Gastroenterology and Urology division. Prior to Medtronic, Mr. Farhat spent 13 years at General Electric (GE) with assignments in multiples businesses, countries and functions. Mr. Farhat earned a bachelor of science degree in international finance and accounting from Northeastern University. He also holds a master s degree in business administration from Harvard University and a master of arts degree in European Union Studies from the Institut National d Etudes Politiques de Paris.
3 John J. Greisch is a corporate vice president and president, International of Baxter International Inc. Mr. Greisch joined Baxter in 2002 as vice president of finance for Baxter s Renal business. He then assumed the role of vice president of finance and strategy for Baxter s BioScience business before being named president of that business. In 2004, he was named corporate vice president and chief financial officer. Prior to joining Baxter, Mr. Greisch was president and CEO of FleetPride Corporation, after completing a distinguished 11-year career at The Interlake Corporation, a diversified global manufacturing company, serving in a variety of roles, including chief financial officer, treasurer, president of Interlake s largest business and president of its European operations based in London. Mr. Greisch received a bachelor s degree in business administration from Miami University at Ohio and a master s degree in Management from Northwestern University s J.L. Kellogg Graduate School of Management. He is a certified public accountant and began his business career with PriceWaterhouseCoopers. Lawrence P. Guiheen is president, BioPharmaceuticals with responsibility for North America sales and marketing for plasma and recombinant therapies in Baxter s BioScience business. Mr. Guiheen joined Baxter in 1978 as a field sales representative in New York City. He has held a variety of positions in sales, marketing and operations in several business units of Baxter in the areas of oncology, diabetes, hematology and immunology. Prior to joining Baxter, Mr. Guiheen was with Alza Pharmaceuticals and earlier with Johnson & Johnson. Mr. Guiheen currently is on the board of the California Healthcare Institute (CHI) and has also held an industry board position in Plasma Protein Therapeutics Association (PPTA). Mr. Guiheen holds a bachelor of science degree in business administration from Rutgers University. David E. Holliday is vice president of marketing, Global Operations and Hemophilia in Baxter s BioScience business. He oversees global communications related to Baxter s hemophilia products, e-business, medical outcomes, pricing and reimbursement, hemophilia marketing and global medical affairs. Mr. Holliday came to Baxter UK in 2003 from Novartis, where he was business unit director for Transplantation, Tissue Engineering & Immunology. Prior to that he was with CIBA Pharmaceuticals. Mr. Holliday has a postgraduate degree in management studies from Kingston University in London.
4 Ronald K. Lloyd is vice president and general manager, BioTherapeutics and Regenerative Medicine in Baxter s BioScience business. He is responsible for the BioSurgery business and Cellular Therapies, which together form the foundation of the Regenerative Medicine franchise. He also is responsible for the strategy/portfolio functions of Baxter s biopharma products. Mr. Lloyd joined Baxter in 2003 as vice president, global marketing for BioPharmaceuticals. Prior to that he was vice president of marketing and business development, International Division for Abbott Laboratories. At Abbott, he also served as director, marketing and business development, cardiovascular and hospital products, and as business unit director for numerous therapeutic areas. Mr. Lloyd earned a master s degree in business administration from Carnegie-Mellon University, and a bachelor s degree from Westminster College. Bruce McGillivray is a corporate vice president of Baxter Healthcare Corporation and president of the company s global Renal business. In this position, he is responsible for the development and worldwide marketing of Baxter s peritoneal and hemodialysis products and services. Mr. McGillivray joined Baxter in 1980 as a territory manager for the Hospital Division in Canada, and throughout the years has held a succession of senior positions. He was named president of Baxter Canada in 1997 and in 2002 was named president of Renal Europe. In 2004, he was appointed to his current position as president of Baxter s global Renal business. Mr. McGillivray has a degree in economics from York University and a master's of business administration from the University of Toronto. Robert L. Parkinson, Jr. is chairman, chief executive officer and president of Baxter International Inc. Prior to joining Baxter in April 2004, Mr. Parkinson was dean of Loyola University Chicago s School of Business Administration and Graduate School of Business. Previously, Mr. Parkinson had a distinguished 25-year career at Abbott Laboratories, serving in a variety of domestic and international management and leadership positions. Mr. Parkinson joined Abbott in 1976 and held a number of marketing and management positions there before being named vice president of European operations in 1990, president of the chemical and agricultural division in 1993 and president of the international division responsible for pharmaceutical, hospital and nutritional products in In 1998 he became a member of its board of directors before being named president and chief operating officer of the company in Mr. Parkinson began his career in 1975 with American Hospital Supply Corporation. Mr. Parkinson is active in numerous business, healthcare industry and community organizations, including serving on the board of directors for Chicago-based Northwestern Memorial HealthCare and the Northwestern Memorial Foundation, as well as Loyola University Chicago s Board of Trustees. He earned both a bachelor s degree and a master s degree in business administration from Loyola University Chicago.
5 Sarah S. Prichard, M.D., is vice president, Global Medical/Clinical Affairs and Research for Baxter s Renal business. She oversees all scientific, clinical and medical affairs globally and advises the company on new and emerging trends in the management of patients with renal disease. She also provides input to product development teams in the design of new products and leads the design of clinical trials. Prior to joining Baxter in 2005, Dr. Prichard served as a member of Baxter s Scientific Advisory Board. She came to Baxter from McGill University, where she served as a professor of medicine, and the Royal Victoria Hospital, where she was senior physician and director of peritoneal dialysis. Dr. Prichard serves on the editorial board of Peritoneal Dialysis International and has served as president of the International Society of Peritoneal Dialysis and president of the Canadian Society of Nephrology. She also has served on the board of trustees and audit committee of Queen s University, as president and university representative for St. Mary s Hospital Board, and on the Governing Council of the Canadian Institutes of Health Research. Dr. Prichard received her medical degree from Queen s University in Kingston, Ontario, and nephrology training at McGill University. Norbert G. Riedel, Ph.D., is a corporate vice president and chief scientific officer of Baxter International Inc., having served in that capacity since Dr. Riedel joined Baxter in 1998 as president of the recombinant unit within Baxter's BioScience business. Prior to joining Baxter, he was head of worldwide biotechnology and worldwide core research functions at Hoechst Marion Roussel, now Sanofi-Aventis. Dr. Riedel received his Ph.D. in biochemistry from the University of Frankfurt in He was a postdoctoral fellow at Harvard University from 1984 to 1987, assistant professor and associate professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991, and a visiting professor at Massachusetts Institute of Technology in He remains affiliated with Boston University as an adjunct professor and also serves as an adjunct professor of medicine at Northwestern University's Feinberg School of Medicine. Dr. Riedel serves on the board of directors of Oscient Pharmaceuticals Corporation and Medigene AG. He is a member of the board of directors of the Illinois Biotechnology Industry Organization and a member of the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology. Daniel Tassé is general manager of the newly formed Baxter Pharmaceuticals & Technologies (BPT) group within Baxter s Medication Delivery business. BPT is the result of the integration of the Anesthesia, Critical Care & Oncology business unit and the BioPharma Solutions business unit into a single pharmaceutical business. Prior to assuming his current position in January 2007, Mr. Tassé served as general manager of Baxter s Anesthesia, Critical Care & Oncology business unit. Mr. Tassé joined Baxter in 2004 from Glaxo SmithKline, where he was vice president and regional director for Australia and New Zealand. Prior to that, he held a number of marketing, sales management; healthcare services management and product development positions in the United States and Canada with Upjohn, SmithKlineBeecham and Glaxo SmithKline. Mr. Tassé received a bachelor s degree in biochemistry from the University of Montreal.
6 Rohit Vishnoi, Ph.D., is vice president, Product Development for Baxter s Renal business. He serves on Baxter s Innovation Council and Senior Technical Leadership team. Dr. Vishnoi joined Baxter in 1988 as a senior principal engineer in the Renal business. He was general manager of the Plasma, Advanced Component Collection and Whole Blood business units in the Baxter s Transfusion Therapies business from 1997 to Prior to his current position, he was VP of Technology Resources for Baxter. Dr. Vishnoi received his master s in management degree in marketing and finance from Northwestern University in Evanston, Illinois, and his doctorate from the Rensselaer Polytechnic Institute in Troy, New York. He received his undergraduate degree in Electrical Engineering from the Indian Institute of Technology in Kanpur, India. Dr. Vishnoi holds several design patents for Baxter products. His team won the 2005 MDEA Award for the ALYX Component Collection System as well as the 1995 R&D 100 Award for their involvement in the HOMECHOICE Peritoneal Dialysis System.
Other appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT.
Executive Committee Guido Oelkers Chief Executive Officer Born 1965. Employed since 2017. PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London,
More informationManagement Team. Bruce C. Cozadd Chairman and Chief Executive Officer
Bruce C. Cozadd Chairman and Chief Executive Officer Bruce Cozadd joined Jazz Pharmaceuticals at its inception and was appointed Jazz Pharmaceuticals Chief Executive Officer in April 2009. From 2003 until
More informationBOARD OF DIRECTORS. PETER WEHRLY Chair
BOARD OF DIRECTORS PETER WEHRLY Chair Peter Wehrly is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). Peter held
More informationRICHARD BUTLAND Director
RICHARD BUTLAND Richard Butland is the managing partner of Kite Capital, a growth oriented private investment firm. Prior to establishing Kite Capital, Richard spent 15 years at Goldman Sachs where he
More informationCASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
More informationLife Sciences Queensland announces latest LSQ Ambassadors
MEDIA RELEASE Monday 22 April, 2013 FOR IMMEDIATE RELEASE Life Sciences Queensland announces latest LSQ Ambassadors (LSQ) is pleased to announce our latest LSQ Ambassadors - two of the life sciences industry
More informationRichard J. Donoghue Senior Vice President for Strategy, Planning and Business Development
Richard J. Donoghue Senior Vice President for Strategy, Planning and Business Development Richard (Rick) J. Donoghue, senior vice president for strategy, planning and business development at NYU Langone
More informationSPEAKERS A S H A B A N G A L O R E
SPEAKERS ASHA BANGALORE Vice President Economist Asha has been an economist with Northern Trust since 1994. Prior to joining Northern Trust, she was a consultant to savings and loan institutions and commercial
More informationMr. Smith Chairman, President, and Chief Executive Officer Southern Bank
Mr. Smith has been chairman, president, and chief executive officer of Southern Bank since 1992. Mr. Smith has 38 years of banking experience and served as president of Alabama Bank from 1980 to 1991.
More informationYevo Scientific Advisory Board
TM Yevo Scientific Advisory Board Dr. Stacey J. Bell Head of the Yevo Scientific Advisory Board Dr. Stacey Bell has been a nutritional consultant from 2008 to 2014, when she joined Yevo International.
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K. DEERE & COMPANY (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report: September 12, 2016
More informationDean A. Connor. President & Chief Executive Officer, Sun Life Financial
Dean A. Connor President & Chief Executive Officer, Sun Life Financial Dean A. Connor was appointed President & Chief Executive Officer, Sun Life Financial on December 1, 2011, and is a member of the company
More informationMSLOC - Global Thought Leader Roundtable ERIC N. FRIDMAN
ERIC N. FRIDMAN Assistant Dean and Director of Marketing for Executive Education, Northwestern University s Kellogg School of Management Eric Fridman is Assistant Dean and Director of Marketing for Executive
More informationBREAKTHROUGH CONVENTION SUMMARY JUNE SAN DIEGO CONVENTION.BIO.ORG #BIO2017
BREAKTHROUGH CONVENTION SUMMARY JUNE 19-22 SAN DIEGO CONVENTION.BIO.ORG #BIO BIO BY THE NUMBERS FEATURING SEVERAL THEMATIC EXHIBITS 16,123 ATTENDEES 74 48 COUNTRIES STATES 18,000 MORE THAN EXHIBITORS 41,400
More informationABRAHAM ABUCHOWSKI, PH.D.
ABRAHAM ABUCHOWSKI, PH.D. Biographical Sketch Dr. Abuchowski is the developer of the current gold standard technology for protein drug delivery called PEGylation. The development of this technology was
More informationBiotech Concerto #6 Investment Process December 2008
Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision
More informationSharon A. Jones, FAHP, CFRE Vice President of Development Haven Hospice Gainesville, FL
Sharon A. Jones, FAHP, CFRE Vice President of Development Haven Hospice Gainesville, FL Sharon Jones started her career in health care fundraising in 1991. She is Vice President of Development at Haven
More informationLIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationThe MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009
The MoneyTree Report Overview of Venture Capital Investments Third Quarter 2009 PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters 1 Host of
More informationOmeros Raises More Than $63 Million in Financing
Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,
More informationVantiv, now Worldpay Investor Relations
Vantiv, now Worldpay Investor Relations Connecting to financial markets Conversing with investors and shareholders Executive Officers Charles Drucker Executive Chairman and Co-Chief Executive Officer Charles
More informationSanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020
PRESS RELEASE Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020 Paris, France May 23, 2016 - Sanofi Chief Executive Officer Olivier Brandicourt, MD, announced today
More informationAgenda. Genesys Capital Partners. The Opportunity. Our Approach
MEDT Dinner Presentation September 28, 2005 Agenda Genesys Capital Partners The Opportunity Our Approach Genesys Capital Partners Genesys Capital Partners Successful Track Record Management experience
More informationGlobal Pharmaceuticals
ROSENFIELD PR OGR AM in public affairs, international relations, and human rights Global Pharmaceuticals February 3 5, 2009 GRINNELL COLLEGE Global Pharmaceutical Symposium February 3-5, 2009 Tuesday,
More informationVisa Inc Investor Day Speaker Biographies
Visa Inc. 2017 Investor Day Speaker Biographies Alfred F. Kelly, Jr. Chief Executive Officer Al Kelly is Chief Executive Officer of Visa Inc. Prior to joining Visa, Mr. Kelly was President and Chief Executive
More informationQI Comes of Age: Health Reform Accelerates
12 th Annual ATP Alumni Conference QI Comes of Age: Health Reform Accelerates February 15-17, 2017 At Newpark Resort in Park City, Utah 2009 ATP Alumni Conference. February 10-12, 2010, Newpark Resort,
More informationANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES
ANNUAL GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES The following items on the agenda of the meeting shall be discussed and/or put to a vote. The numbers in the list correspond to the numbers on the
More informationGovernment Priorities of the Day - Budget 2018 Speaker Biographies
Government Priorities of the Day - Budget 2018 Speaker Biographies Janique Caron, Assistant Comptroller General, Financial Management Sector, Treasury Board Secretariat Janique joined the Treasury Board
More informationTHE GOLDMAN SACHS GROUP, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationANNUAL GENERAL MEETING OF SHAREHOLDERS AFFIMED N.V.
ANNUAL GENERAL MEETING OF SHAREHOLDERS AFFIMED N.V. to be held on Tuesday, June 19, 2018 at 15:00 hrs. (CET) at Amsterdam Marriott Hotel, Stadhouderskade 12, 1054 ES Amsterdam, the Netherlands Agenda 1
More informationCronos Capital
Cronos Capital overview Overview Cronos Group, formerly known as PharmaCan Capital Corp., is a vertically integrated cannabis company with great geographical diversification as the foundation for growth
More informationTransforming the right molecules into the best medicines TM
August 2017 Transforming the right molecules into the best medicines TM We are passionate in our mission to improve the health of patients by providing novel strategic alternatives to companies wishing
More informationEXECUTIVE COMMITTEE. David Wan. Maureen Betses. President & Chief Executive Officer. Executive Vice President, Higher Education
David Wan President & Chief Executive Officer David Wan is chief executive officer of Harvard Business Publishing. He joined the company in July 2002. Wan is a distinguished operating executive with 30
More informationFinal Pitch Competition PROGRAM GUIDE. Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV
Final Pitch Competition PROGRAM GUIDE Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV #HITVenture #HIMSS16 1 Presented by: WEDNESDAY, MARCH
More informationPeter Smith. He has two daughters, Natalie and Christina, both of whom played for the McGill Martlets.
MANAGEMENT FORUM CONFERENCE LEADERS TEAMS AND LIFE NOVEMBER 17 2010 Peter Smith Peter Smith, a native of Lachine, Que., was appointed head coach at McGill University in 1999 and took a one-year sabbatical
More informationDealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.
Dealdoc Acquisition agreement for Gambro Baxter International Gambro Dec 04 2012 Acquisition agreement for Gambro Companies: Baxter International Gambro Announcement date: Dec 04 2012 Deal value, US$m:
More informationIgor Fisch. New candidate, independent
Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF
More information2016 ICGN Annual General Meeting
Item 14, June ICGN Board Meeting 2016 ICGN Annual General Meeting Composition of the Nomination Committee Erik Breen, Chair, ICGN Board of Governors The ICGN Nomination Committee is constituted in accordance
More informationJOHN JACK R. TUPMAN, JR CURRICULUM VITAE
JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant
More informationPHARMA COMPANIES. Bristol-Myers Squibb. CAE Healthcare. Hoffmann-LaRoche
People on themove PHARMA COMPANIES Jacques Dessureault, former General Manager, Med Plan, has been appointed Vice-President, Cardiovascular/Metabolic Business Unit, at Bristol- Myers Squibb. James O. McPherson,
More informationVIable Solutions: Six steps to transform healthcare now. Speaker Biographies
VIable Solutions: Six steps to transform healthcare now Speaker Biographies Andy Baskin, M.D. National Medical Director for Quality Performance Aetna Andrew Baskin is Aetna s National Medical Director
More informationBaxter International Inc. Annual Meeting of Shareholders May 1, 2007
Baxter International Inc. Annual Meeting of Shareholders May 1, 2007 2007 Annual Meeting of Shareholders Introductions and Meeting Procedures 2007 Annual Meeting Proposals Election of Four Directors Appointment
More informationThe Annual Irish America HEALTHCARE & LIFE SCIENCES 50
IRISH AMERICA MAGAZINE invites you to an awards dinner for The Annual Irish America HEALTHCARE & LIFE SCIENCES 50 THE NEW YORK YACHT CLUB 37 West 44 th Street New York City FRIDAY, November 2 nd, 2018
More informationKoen Dejonckheere. Professional experience. Board Memberships. Education
Koen Dejonckheere Professional experience KBC SECURITIES GROUP 2002-2008 Managing Director, responsible for Corporate Finance Previously, Koen Dejonckheere was active in Corporate Finance and Private Equity
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationForm FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.
Form 51-102FI SERNOVA CORP. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. The following discussion and analysis should be
More informationBob McDonald. Position Held & Dates. Chairman of the Board President and Chief Executive Officer, P&G. Residence Cincinnati, Ohio, USA
Bob McDonald President and Chief Executive Officer, Position Held & Dates Residence Cincinnati, Ohio, USA Date of Birth June 20, 1953 Place Gary, Indiana, USA Education U.S. Military Academy B.S., 1975
More informationGenerex Announces Appointment of Executive Management Team
Generex Announces Appointment of Executive Management Team Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth MIRAMAR, FL, November 15, 2018 -- Generex Biotechnology Corporation
More informationASX Group Clearing and Settlement Boards
ASX Group Clearing and Settlement Boards Name of Director Qualifications Experience ASX Group Other Listed Company Rick Holliday-Smith BA (Hons), FAICD A specialist in capital markets, derivatives and
More informationPeople. Move PHARMA COMPANIES. on the. Abbott Nutrition International. AstraZeneca. Axcan Pharma. Berlex. Bristol-Myers Squibb
People on the Move PHARMA COMPANIES Gary Schmid Abbott Nutrition International Crawford Wright AstraZeneca Abbott Nutrition International Gary Schmid, formerly Director of Marketing, Primary Care Division,
More informationTRANSLATIONAL SCIENCE
TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM
More informationFORWARD LOOKING STATEMENTS
1 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no express or implied representation orwarrant as to the completeness of this information
More informationLehigh University Team biographies. October 30, 2017
Lehigh University Team biographies October 30, 2017 Core team members 2 Lane McBride Partner and Managing Director, Washington, DC Lane McBride is a Partner and Managing Director in the Washington, D.C.
More informationMANAGING DIRECTOR 360 MADISON AVENUE NEW YORK, NY
Matthew Goldreich MANAGING DIRECTOR MGOLDREICH@CAINBROTHERS.COM 360 MADISON AVENUE NEW YORK, NY 10017 212.981.6946 Matt joined Cain Brothers in 1995 and is one of the longest tenured bankers at the firm.
More informationSan Diego. March 2, American College of Surgeons Surgical Health Care Quality Forum. American College of Surgeons
American College of Surgeons Inspiring Quality: Highest Standards, Better Outcomes American College of Surgeons Surgical Health Care Quality Forum San Diego March 2, 2012 Scripps Memorial Hospital La Jolla
More informationManagement to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
More informationCelebrating International Women's Day Friday, March 8, :30am-1:00pm
Co-Hosted by: Join us in Launching the 1st Annual Successful Women of San Diego Executive Leadership Panel Celebrating International Women's Day Friday, March 8, 2019 11:30am-1:00pm Sponsored by: Location:
More informationShareholders are invited to the 2018 Annual Meeting which is scheduled for 27 September 2018.
7 September 2018 Dear Shareholder 2018 Annual Meeting of Shareholders Shareholders are invited to the 2018 Annual Meeting which is scheduled for 27 September 2018. The details of the Annual Meeting are
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationTHE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES
THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES Join us for a very special program co-hosted the HBS Alumni of Boston (HBSAB), The Harvard Stem Cell Institute (HSCI), and the Harvard NeuroDiscovery
More informationBob McDonald. Bob has focused P&G on winning with consumers where it matters most with products that improve their lives every day.
Bob McDonald President and Chief Executive Officer, Bob has focused on winning with consumers where it matters most with products that improve their lives every day. Bob believes s core strengths are key
More informationNVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations
February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and
More informationStudy overview. The Global Biomedical Industry: Preserving U.S. Leadership
Presentation for: Voluntary Health Leadership Conference February 9, 2012 Rancho Bernardo Inn San Diego, CA Ross DeVol Chief Research Officer Milken Institute Study overview Part 1: Understanding the Factors
More informationDraft Program Netherlands Economic Mission to the United States
Sunday May 31, 2015 Chicago and Grand Rapids Flight Amsterdam- Chicago KL0611 Arrival at Chicago airport (ORD) Transfer to Grand Rapids (Michigan) Check-in at hotel Grand Rapids Welcoming Reception - Informal
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date
More informationB i o g r a p h y Steven M. Egna Steven M. Egna
B i o g r a p h y Steven M. Egna CBA, CVA, ABAR, CM&AA Valuation Resource Group, LLC 75 Troy Road East Greenbush, New York 12061 P: (518) 479-1008 E: segna@valuationresource.com Steven M. Egna is a Certified
More informationWhere the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes
Where the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes Scientific innovation is at the heart of everything we do. Scientific innovation is at the heart of our business and
More informationInvitation to the Extraordinary General Meeting of UBS AG
Invitation to the Extraordinary General Meeting of UBS AG Thursday, 2 October 2008, 10:30 a.m. (Doors open at 9:30 a.m.) St. Jakobshalle Brüglingerstrasse 21, Basel Status Report of the Board of Directors
More informationSeptember 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board
AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT
More informationRI President Ian Riseley
RI President Ian Riseley Ian H.S. Riseley is a chartered accountant and principal of Ian Riseley and Co., a firm he established in 1976. He has a master s degree in taxation law and graduate diplomas in
More informationAssociate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive
Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager
More informationNIHR ROADSHOW FOR MEDTECH SMES
MARTIN HUNT, DIRECTOR FOR INVENTION FOR INNOVATION (i4i) PROGRAMME, NATIONAL INSTITUTE FOR HEALTH RESEARCH Martin is Programme Director for i4i, a translational funding programme. i4i aims to support and
More informationTHE REGIONAL ECONOMIC BRIEFING FEDERAL RESERVE BANK OF NEW YORK SPEAKERS BIOGRAPHIES AT THE 33 LIBERTY STREET NEW YORK, NY
THE REGIONAL ECONOMIC BRIEFING AT THE FEDERAL RESERVE BANK OF NEW YORK SPEAKERS BIOGRAPHIES FEDERAL RESERVE BANK OF NEW YORK 33 LIBERTY STREET NEW YORK, NY 10045 WWW.NEWYORKFED.ORG THURSDAY, JULY 22, 2010
More informationComprehensive Research Services
Comprehensive Research Services Scripps Health: At the Forefront of Clinical Research Scripps Health is a recognized leader in clinical research and has long been at the forefront of numerous medical breakthroughs.
More informationADDRESSING THE DIVERSE HEALTH AND WELL-BEING CHALLENGES OF WOMEN AROUND THE WORLD 22 FEBRUARY 2016
ADDRESSING THE DIVERSE HEALTH AND WELL-BEING CHALLENGES OF WOMEN AROUND THE WORLD 22 FEBRUARY 2016 Welcome Dear all, I am delighted to welcome you to Merck Consumer Health s first Global Consumer Health
More informationBreakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC
Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC Study overview Part 1: The Global Biomedical Industry: Understanding the
More informationWASHINGTON,D.C FORM8-K. CURRENTREPORT PursuanttoSection13or15(d)ofthe. Date of Report (Date of the earliest event reported): October29,2018
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 Date of Report (Date of the earliest event reported):
More informationScripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011
Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic
More informationFEBRUARY 9-11, Beyond the Basics
FEBRUARY 9-11, 2018 Beyond the Basics On behalf of the students, staff, and faculty here in the Edward P. Fitts Department of Industrial and Systems Engineering at NC State, I would like to welcome you
More informationAAON BOARD OF DIRECTORS
AAON BOARD OF DIRECTORS Norman H. Asbjornson has served as Chief Executive Officer and a director of AAON since 1989, and currently serves in the class of directors whose terms will expire at the 2021
More informationWOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
More informationLISA TILTON-McCARTHY
LISA TILTON-McCARTHY Lisa Tilton-McCarthy received a B.A. in English from Texas A&M University in College Station and graduated summa cum laude from South Texas College of Law in Houston. She was Editor-in-Chief
More informationDIRECTORS EDUCATION PROGRAM
DEP 71 MODULE III DIRECTORS EDUCATION PROGRAM FACULTY BIOGRAPHIES National Academic Director Richard C. Powers M.B.A. (Queen's University), L.LB. (Queen's University), ICD.D Profit Governance Essentials
More informationBaxter International Inc. / Letter to Stockholders / Baxter International Inc. / Letter to Shareholders /
Baxter International Inc. / Letter to Stockholders / www.baxter.com Baxter International Inc. / Letter to Shareholders / www.baxter.com HOSPITAL PRODUCTS Baxter manufactures products used in the delivery
More informationDirectors and Senior Management
Directors and Senior Management Victor FUNG Kwok King Group Non-Executive Chairman Victor FUNG Kwok King, aged 56, brother of Dr William FUNG Kwok Lun, is Group Chairman. He joined the Group in 1973 as
More informationSPEAKER BIOGRAPHIES. Sarah Abbas
SPEAKER BIOGRAPHIES Sarah Abbas Sarah Abbas currently supports global medical education through collaboration with Pfizer Country Offices. She developed and managed the WW Investigator Initiated Research
More informationRaymond A. Snead, Jr., D. Sc., FHFMA, FACHE
Doctor of Healthcare Administration and currently practicing CFO whose thirty-five-year career includes serving as the President, Executive Vice President and Chief Financial Officer of for profit and
More informationDirectors and Senior Management
Directors and Senior Management Victor FUNG Kwok King Group Non-Executive Chairman Victor FUNG Kwok King, aged 57, brother of Dr William FUNG Kwok Lun, is Group Chairman. He joined the Group in 1973 as
More informationReinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &
More informationBiographies of Directors and Senior Management
ANNUAL REPORT 2010 07 EXECUTIVE DIRECTORS Mr. WANG Jianzhou Age 62, Executive Director and Chairman of the Company, joined the Board of Directors of the Company in November 2004. Mr. Wang is in charge
More informationWarren Murrell. President and CEO
President and CEO Warren Murrell As president and CEO for Peoples Health, Warren Murrell is the driving force behind the Peoples Health business model and is focused on making a positive impact on the
More informationCandidate Profile Form District Committee Election Joel Glasco
Candidate Profile Form District Committee Election Joel Glasco Candidate Name: Title: Managing Director - Market Manager Firm: Wells Fargo Adviso Candidate Biography and Personal Statement Candidate Biography
More information2015 Real Estate Industry Update A landscape for change: Transforming for the future
2015 Real Estate Industry Update A landscape for change: Transforming for the future September 17, 2015 Welcome Welcome to Deloitte s 2015 real estate industry update The real estate industry has been
More informationIndiana University School of Public and Environmental Affairs Dean s Council Members. David Wang, Chair
Indiana University School of Public and Environmental Affairs Dean s Council Members David Wang, Chair David Wang is a Senior Operating Partner of Atlas Holdings, a private equity investment firm that
More informationHFMA January CFO Forum
HFMA January CFO Forum January 26, 2018 St. Mark s Hospital Education Auditorium 1200 E. 3900 S. Salt Lake City, Utah 7.0 CPE hours 7:30 8:00 a.m. Continental Breakfast 8:00 8:15 a.m. Opening and Chapter
More informationPlenary Session III: Dispelling Myths around the FINRA Board Monday, May 21 4:15 p.m. 5:15 p.m.
Plenary Session III: Dispelling Myths around the FINRA Board Monday, May 21 4:15 p.m. 5:15 p.m. During this session, panelists discuss what goes on at a FINRA Board meeting. Moderator: Panelist: Marcia
More informationConference Speakers. Bo Armstrong, DataPath, Director of Marketing
Conference Speakers Bo Armstrong, DataPath, Director of Marketing Bo Armstrong leads all marketing initiatives for DataPath and its subsidiaries. He joined DataPath in 2015 and has over 15 years of marketing
More informationPRESENTERS >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
PRESENTERS >>>>>>>>>> Paula Rosput Reynolds President and Chief Executive Officer Mike Hughes Executive Vice President Insurance Operations Paula Rosput Reynolds is president and chief executive officer
More informationEnhancing Ontario s World-Class Health Care Technology Sector
BACKGROUNDER Ministry of Research and Innovation Enhancing Ontario s World-Class Health Care Technology Sector November 19, 2013 The new Ontario Health Innovation Council unites experts from the health
More information